# Ziegler Meditech Equity Partners

> Ziegler Meditech Equity Partners is a VC fund backing Health Care. See 6 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: Milwaukee, United States
- Total investments: 6
- Last investment: May 2010
- Lead investor: 33%
- Last updated: Aug 2026
- Website: https://www.ziegler.com/

Ziegler Meditech Equity Partners is a VC fund in Milwaukee focused on Health Care and Biotechnology. ZMEP is a limited partnership focusing on equity and equity-like investments in emerging medical device technologies. ZMEP invests globally drawing on the years of investing experience of its management team. With over 50 years of experience in medical device development and commercialization, the ZMEP management team has the ability to seek outand partner with leading entrepreneurs in the medical device field. With offices in the United States and Israel, ZMEP is positioned globally to partner with middle to late stage medical device companies showing great promise for success through commercialization.

## Contacts

5 contacts available for Ziegler Meditech Equity Partners. Shizune tracks 4 team members at Ziegler Meditech Equity Partners. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/ziegler-meditech-equity-partners?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Health Care | 2 | 33% |
| Biotechnology | 2 | 33% |
| Mobile | 1 | 17% |
| Medical | 1 | 17% |
| Wireless | 1 | 17% |

9 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series C | 1 | 17% |
| Series E | 1 | 17% |
| Series F | 1 | 17% |
| Funding Round | 1 | 17% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United States | 2 | 33% |
| Israel | 1 | 17% |

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Donald I. Grande | Chief Administrative Officer | 0 | https://shizune.co/investors/profile/donald-i-grande |
| Eitan Machover | Team member | 0 | https://shizune.co/investors/profile/eitan-machover |
| Samuel Cubac | Managing Director | 0 | https://shizune.co/investors/profile/samuel-cubac |
| S. Charles O’Meara | Managing Director | 0 | https://shizune.co/investors/profile/s-charles-omeara |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Aposense | Aposense (formerly NST) is a clinical-stage molecular imaging and drug development company, with a pipeline of products based on its patented platform technology for targeting apoptosis (programmed cell death) in vivo. The company translating the science of Apoptosis (programmed cell death) into personalized patient care in multiple diseasecategories, including oncology, cardiology, and neurology. Targeting of this important biological process in-vivo opens opportunities for real-time clinical imaging of disease activity and targeted therapy.Aposense specializing in the development of novel drugs and utilizing membrane electrical forces for trans-membrane of macromolecule drugs, mainly siRNA. It also developed rationally-designed molecular nano-motors (MNMs), being novel small-molecule chemical entities and its translation into kinetic energy for movement within the hydrophobic membrane core.Aposense was founded in 1996 and is headquartered in Petah Tiqva, HaMerkaz, Israel. | $3M |  | May 23, 2010 |  |
| MobileAccess Networks | MobileAccess provides enterprise wireless network solution. MobileAccess brings the wireless signals from the outside indoors and then distributes them through a series of discreet antennas located throughout the facility. | $7M | Series F | Dec 15, 2009 |  |
| Aposense | Aposense (formerly NST) is a clinical-stage molecular imaging and drug development company, with a pipeline of products based on its patented platform technology for targeting apoptosis (programmed cell death) in vivo. The company translating the science of Apoptosis (programmed cell death) into personalized patient care in multiple diseasecategories, including oncology, cardiology, and neurology. Targeting of this important biological process in-vivo opens opportunities for real-time clinical imaging of disease activity and targeted therapy.Aposense specializing in the development of novel drugs and utilizing membrane electrical forces for trans-membrane of macromolecule drugs, mainly siRNA. It also developed rationally-designed molecular nano-motors (MNMs), being novel small-molecule chemical entities and its translation into kinetic energy for movement within the hydrophobic membrane core.Aposense was founded in 1996 and is headquartered in Petah Tiqva, HaMerkaz, Israel. | $7.3M |  | Aug 20, 2008 |  |
| MAKO Surgical | MAKO Surgical is a medical device company, markets its advanced robotic arm solution, joint specific applications for the knee and hip, and orthopedic implants for orthopedic procedures in the United States and internationally. The company offers MAKOplasty, a restorative surgical solution that enables orthopedic surgeons to treat patient specificosteoarthritic disease. It also provides robotic arm interactive orthopedic system (RIO) consisting of a tactile robotic arm utilizing an integrated bone cutting instrument; and a patient specific visualization component, which offers pre-operative and intra-operative guidance to the orthopedic surgeon, enabling tissue sparing bone removal, and accurate implant insertion and alignment.In 2011, The company was named the No.1 on the Technology Fast 500 as the fastest growing technology company by Deloitte and received the CSSEC Award for loyal, customer-focused staff members presented by the Technology Services Industry Association and ACE Award (Achievement in Customer Excellence) from MarketTools and Fast Tech Award as one of the 25 fastest growing technology companies in South Florida by South Florida Business Journal.MAKO Surgical was founded in 2004 and is headquartered in Florida, USA. | $30M | Series C | Feb 06, 2007 |  |
| Aposense | Aposense (formerly NST) is a clinical-stage molecular imaging and drug development company, with a pipeline of products based on its patented platform technology for targeting apoptosis (programmed cell death) in vivo. The company translating the science of Apoptosis (programmed cell death) into personalized patient care in multiple diseasecategories, including oncology, cardiology, and neurology. Targeting of this important biological process in-vivo opens opportunities for real-time clinical imaging of disease activity and targeted therapy.Aposense specializing in the development of novel drugs and utilizing membrane electrical forces for trans-membrane of macromolecule drugs, mainly siRNA. It also developed rationally-designed molecular nano-motors (MNMs), being novel small-molecule chemical entities and its translation into kinetic energy for movement within the hydrophobic membrane core.Aposense was founded in 1996 and is headquartered in Petah Tiqva, HaMerkaz, Israel. | $12M |  | Nov 09, 2006 |  |
| MobileAccess Networks | MobileAccess provides enterprise wireless network solution. MobileAccess brings the wireless signals from the outside indoors and then distributes them through a series of discreet antennas located throughout the facility. | $11M | Series E | Jun 13, 2006 |  |

6 of 6 investments shown.

## Co-investors
- [DeA Capital](https://shizune.co/investors/profile/dea-capital) — VC Fund, 2 deals together
- [Eurofund](https://shizune.co/investors/profile/eurofund) — VC Fund, 2 deals together
- [HarbourVest Partners](https://shizune.co/investors/profile/harbourvest-partners) — VC Fund, 2 deals together
- [Pitango VC](https://shizune.co/investors/profile/pitango-venture-capital) — VC Fund, 2 deals together
- [Pontifax](https://shizune.co/investors/profile/pontifax) — VC Fund, 2 deals together
- [Aperture Venture Partners](https://shizune.co/investors/profile/aperture-venture-partners) — VC Fund, 1 deal together

## Similar investors

### Similar industry
- [SOSV](https://shizune.co/investors/profile/sosv) — VC Fund
- [ARCH Venture Partners](https://shizune.co/investors/profile/arch-venture-partners) — VC Fund
- [OrbiMed](https://shizune.co/investors/profile/orbimed-advisors) — VC Fund

### Similar stage
- [Sequoia Capital](https://shizune.co/investors/profile/sequoia-capital) — VC Fund
- [New Enterprise Associates](https://shizune.co/investors/profile/new-enterprise-associates) — VC Fund
- [Bessemer Venture Partners](https://shizune.co/investors/profile/bessemer-venture-partners) — VC Fund

### Similar country
- [F6 Ventures](https://shizune.co/investors/profile/flat6labs) — VC Fund
- [Oqal](https://shizune.co/investors/profile/oqal) — VC Fund
- [Alesta Yatırım](https://shizune.co/investors/profile/alesta-girisim) — VC Fund

## Featured in investor lists
- [Medical Investors in Middle East](https://shizune.co/investors/medical-investors-middle-east)
- [Medical VC Funds in Middle East](https://shizune.co/investors/medical-vc-funds-middle-east)
- [Medical Investors in Israel](https://shizune.co/investors/medical-investors-israel)
- [Medical VC Funds in Israel](https://shizune.co/investors/medical-vc-funds-israel)
- [Biotechnology Investors in Middle East](https://shizune.co/investors/biotechnology-investors-middle-east)
- [Biotechnology VC Funds in Middle East](https://shizune.co/investors/biotechnology-vc-funds-middle-east)

## FAQ

### What does Ziegler Meditech Equity Partners invest in?

Ziegler Meditech Equity Partners invests primarily in Health Care, Biotechnology and Mobile startups, most often at Series C and Series E stage. Most of the 6 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact Ziegler Meditech Equity Partners?

Public channels for Ziegler Meditech Equity Partners include the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at Ziegler Meditech Equity Partners?

The team at Ziegler Meditech Equity Partners includes Donald I. Grande (Chief Administrative Officer), Eitan Machover (Team member) and Samuel Cubac (Managing Director). The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co